Clinical Trial Update: Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sintilimab plus anlotinib for initially unresectable non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: UNKNOWN